

1. **Which of the following are risk factors for developing glaucoma?**
 - a. Family history of glaucoma
 - b. Extreme nearsightedness
 - c. Diabetes
 - d. All of the above
 2. **Where is aqueous humor stored in the eye?**
 - a. Anterior chamber
 - b. Posterior chamber
 - c. Choroid
 - d. Both A and B
 3. **Aqueous humor outflow is regulated by:**
 - a. Trabecular meshwork and uveoscleral outflow
 - b. Uveoscleral outflow only
 - c. Trabecular meshwork only
 - d. Schlemm's canal
 4. **Increased intraocular pressure may cause vision loss through:**
 - a. Excessive drainage from the tear ducts
 - b. Damage to the optic nerve
 - c. Corneal occlusion
 - d. Discoloration of the iris
 5. **The intraocular pressure of an average person without glaucoma is:**
 - a. 20-40 mmHg
 - b. 10-21 mmHg
 - c. 5-15 mmHg
 - d. 40-60 mmHg
 6. **Which of the following are characteristics of closed-angle glaucoma?**
 - a. Obstructed position of iris with angle of 240 degrees
 - b. No change in intraocular pressure
 - c. Dilated pupil which is poorly receptive to light
 - d. Rarely results in vision loss
 7. **Which of the following are risk factors for closed-angle glaucoma?**
 - a. Male sex
 - b. Female sex
 - c. Family history of closed-angle glaucoma
 - d. Global warming
 8. **Which of the following is not a drug class used to lower intraocular pressure in glaucoma?**
 - a. Prostaglandin analog
 - b. Nonselective Beta Agonists
 - c. Alpha-2 agonists
 - d. Carbonic anhydrase inhibitors
 9. **What choice below is generally considered a last option for the treatment of glaucoma?**
 - a. Prostaglandin analog
 - b. Nonselective Beta Agonists
 - c. Alpha-2 agonists
 - d. Oral Carbonic anhydrase inhibitors
 10. **What is a characteristic of prostaglandin analogs?**
 - a. Decrease aqueous uveoscleral outflow
 - b. Increase trabecular outflow
 - c. Reduce baseline IOP by 10-20%
 - d. Requires frequent dosing
 11. **Which of the following are characteristics of Beta-blockers?**
 - a. May cause blurred vision
 - b. May cause systemic adverse effects
 - c. Tachyphylaxis may develop from prolonged use
 - d. All of the Above
 12. **Which of the following beta blockers are not used in the treatment of glaucoma?**
 - a. Timolol
 - b. Carvedilol
 - c. Carteolol
 - d. Levobunolol
-

13. Which of the following are characteristics of alpha agonists?

- a. Apraclonidine increases uveoscleral outflow
- b. Lower IOP by 15-20%
- c. Requires BID to TID dosing
- d. All of the above

14. Which of the following are true about topical carbonic anhydrase inhibitors?

- a. Block secretion of sodium and bicarbonate ions of the ciliary body
- b. Must only be used as adjunct therapy
- c. Lower IOP as much as beta-blockers
- d. Should be used in conjunction with systemic carbonic anhydrase inhibitors

15. Which one of the following is true about nasolacrimal occlusion?

- a. The technique eliminates drug side effects.
 - b. It is required with use for any eye drop.
 - c. It is intended to reduce the immediate loss of drug through tear ducts.
 - d. A patient need only maintain the occlusion for 30 seconds.
-

Participant Information:

AL License # _____

Name _____

Address _____

City _____ State _____ Zip _____

E-mail _____

NABP e-Profile # _____

MM/DD (month/day of birth) _____

How long did it take you to read the article and complete this test?

_____ hours _____ minutes

My signature certifies that I have independently taken this CE examination.

| CE Assessment Answers | | | | |
|--|---|---|---|---|
| Please circle your answers (one answer per question) | | | | |
| 1. | A | B | C | D |
| 2. | A | B | C | D |
| 3. | A | B | C | D |
| 4. | A | B | C | D |
| 5. | A | B | C | D |
| 6. | A | B | C | D |
| 7. | A | B | C | D |
| 8. | A | B | C | D |
| 9. | A | B | C | D |
| 10. | A | B | C | D |
| 11. | A | B | C | D |
| 12. | A | B | C | D |
| 13. | A | B | C | D |
| 14. | A | B | C | D |
| 15. | A | B | C | D |

Program Evaluation – Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- | | | | | |
|-----------------------------------|---|---|---|---|
| 1. Overall quality of the article | 1 | 2 | 3 | 4 |
| 2. Relevance to pharmacy practice | 1 | 2 | 3 | 4 |
| 3. Value of the content | 1 | 2 | 3 | 4 |

Please answer each question, marking whether you agree or disagree.

4. This course met the learning objectives. Agree Disagree
5. The article did not promote a particular product or company. Yes No

Impact of the Activity

The information presented (check all that apply):

6. Reinforced my current practice/treatment habits Will improve my practice/patient outcomes
 Provided new ideas or information I expect to use Adds to my knowledge
7. Will the information presented cause you to make any changes in how you do your job? Yes No
8. How committed are you to making these changes?
 (Not committed) 1 2 3 4 (Very committed).
9. Do you feel future activities on this subject matter are necessary and/or important? Yes No

Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

Yes No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.